Quick Answer
CASI Pharmaceuticals, Inc. reported Cash and Equivalents of $13.47 million for fiscal year 2024.
CASI Pharmaceuticals, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2024 | $13.47M | -21.2% |
| 2023 | $17.08M | -63.7% |
| 2022 | $47.11M | +21.7% |
| 2021 | $38.70M | — |
- CASI Pharmaceuticals, Inc. showed a decrease of -21.2% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2021–2024 period, CASI Pharmaceuticals, Inc.’s cash and equivalents has declined by 65.2% (from $38.70 million to $13.47 million).
- The most recent figure is from CASI Pharmaceuticals, Inc.’s fiscal year 2024 report (Form 20-F), filed with the SEC on March 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: